Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics. KTH, Centres, Science for Life Laboratory, SciLifeLab.
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Affinity Proteomics.ORCID iD: 0000-0003-0880-5375
Show others and affiliations
2018 (English)In: Lung Cancer, ISSN 0169-5002, E-ISSN 1872-8332, Vol. 125, p. 157-163Article in journal (Refereed) Published
Abstract [en]

Objectives: Cancer-testis antigens (CTAs) are defined as proteins that are specifically expressed in testis or placenta and their expression is frequently activated in cancer. Due to their ability to induce an immune response, CTAs may serve as suitable targets for immunotherapy. The aim of this study was to evaluate if there is reactivity against CTAs in the plasma of non-small cell lung cancer (NSCLC) patients through the detection of circulating antibodies. Materials and methods: To comprehensively analyze autoantibodies against CTAs the multiplexing capacities of suspension bead array technology was used. Bead arrays were created with 120 protein fragments, representing 112 CTAs. Reactivity profiles were measured in plasma samples from 133 NSCLC patients and 57 cases with benign lung diseases. Results: Altogether reactivity against 69 antigens, representing 81 CTAs, was demonstrated in at least one of the analyzed samples. Twenty-nine of the antigens (45 CTAs) demonstrated exclusive reactivity in NSCLC samples. Reactivity against cancer-testis antigen family 47; member A (CT47A) genes, P antigen family member 3 (PAGE3), variable charge X-linked (VCX), melanoma antigen family B1 (MAGEB1), lin-28 homolog B (LIN28B) and chromosome 12 open reading frame 54 (C12orf54) were only found in NSCLC patients at a frequency of 1%–4%. The presence of autoantibodies towards these six antigens was confirmed in an independent group of 34 NSCLC patients. Conclusion: We identified autoantibodies against CTAs in the plasma of lung cancer patients. The reactivity pattern of autoantibodies was higher in cancer patients compared to the benign group, stable over time, but low in frequency of occurrence. The findings suggest that some CTAs are immunogenic and that these properties can be utilized as immune targets. 

Place, publisher, year, edition, pages
Elsevier Ireland Ltd , 2018. Vol. 125, p. 157-163
Keywords [en]
Adenocarcinoma, Cancer immunity, Lung cancer, MAGE, Squamous cell cancer, Tumor markers
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:kth:diva-236616DOI: 10.1016/j.lungcan.2018.09.012ISI: 000450378500023Scopus ID: 2-s2.0-85054035205OAI: oai:DiVA.org:kth-236616DiVA, id: diva2:1264017
Funder
Science for Life Laboratory - a national resource center for high-throughput molecular bioscienceKnut and Alice Wallenberg FoundationSwedish Cancer Society, 2012/738
Note

Export Date: 22 October 2018; Article; CODEN: LUCAE; Correspondence Address: Djureinovic, D.; Department of Immunology, Genetics and Pathology, Uppsala UniversitySweden; email: dijana.djureinovic@igp.uu.se; Funding details: SciLifeLab, Science for Life Laboratory; Funding details: Knut och Alice Wallenbergs Stiftelse; Funding details: 2012/738, Cancerfonden; Funding text: This study was supported by the Swedish Cancer Society Cancerfonden (2012/738), Lions Cancer Foundation Uppsala, Sweden, Erik, Karin and Gösta Selanders Foundation, Sweden as well as grants for SciLifeLab and the Human Protein Atlas funded by the Knut and Alice Wallenberg foundation.; Funding text: We thank the Human Protein Atlas team, the Uppsala Biobank and everyone in the Division of Affinity Proteomics and the Autoimmunity Profiling facility at SciLifeLab for their support. Appendix A. QC 20181119

Available from: 2018-11-19 Created: 2018-11-19 Last updated: 2018-12-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records BETA

Dodig-Crnkovic, TeaHellström, CeciliaSchwenk, Jochen M.

Search in DiVA

By author/editor
Dodig-Crnkovic, TeaHellström, CeciliaSchwenk, Jochen M.
By organisation
Affinity ProteomicsScience for Life Laboratory, SciLifeLab
In the same journal
Lung Cancer
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 220 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf